Paydas S, Kiliç B, Sahin B, Buğdayci R
Cukurova University, Faculty of Medicine, Department of Oncology, Balcali, Adana, Turkey.
Br J Cancer. 1999 Jul;80(9):1303-5. doi: 10.1038/sj.bjc.6690522.
Anti-hepatitis C virus (HCV) antibody prevalence was investigated in 228 patients with lymphoproliferative disorders (LPDs). Twenty-six of 228 (11.40%) patients with LPDs were positive for anti-HCV which was higher than the donor population (P = 0.0007). Nine of 98 cases with non-Hodgkin's lymphoma, five of 47 cases with multiple myeloma, seven of 36 cases with Hodgkin's disease, four of 38 cases with chronic lymphocytic leukaemia and one of nine cases with acute lymphoblastic leukaemia had anti-HCV antibody. In all patients, odds ratio (OR) for anti-HCV was 24.09. This value was higher in patients less than 35 years as 62.04 for below 25 years and 32.00 for between 25-35 years. Our findings suggest that HCV infection might be a causative and/or contributing factor in lymphoproliferation.
对228例淋巴增殖性疾病（LPD）患者进行了抗丙型肝炎病毒（HCV）抗体流行率调查。228例LPD患者中有26例（11.40%）抗HCV呈阳性，高于供体人群（P = 0.0007）。98例非霍奇金淋巴瘤患者中有9例、47例多发性骨髓瘤患者中有5例、36例霍奇金病患者中有7例、38例慢性淋巴细胞白血病患者中有4例以及9例急性淋巴细胞白血病患者中有1例抗HCV抗体呈阳性。在所有患者中，抗HCV的比值比（OR）为24.09。该值在35岁以下患者中更高，25岁以下为62.04，25 - 35岁之间为32.00。我们的研究结果表明，HCV感染可能是淋巴增殖的一个致病和/或促成因素。
